Sculptor Capital’s BioNTech BNTX Stock Holding History

Sculptor Capital’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,000	Closed	-$163K	–	705
2020 Q4	$163K	Buy	+2,000	New	+$196K	﹤0.01%	458

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Sculptor Capital's BNTX Position: Q1 2021 in Review

Sculptor Capital sold out of BioNTech (BNTX) in Q1 2021, closing a stake of 2,000 shares — an estimated $163K sold.

Sculptor Capital first reported a position in BNTX in Q4 2020 and held it in 1 quarter. The position peaked at $163K in Q4 2020. 225 funds tracked by Wall St. Rank hold BNTX as of Q1 2021.

Sculptor Capital reported no remaining BioNTech position as of Q1 2021 after selling out during the quarter.
Sculptor Capital sold 2,000 BioNTech shares in Q1 2021, an estimated $163K.
Sculptor Capital first reported a position in BioNTech in Q4 2020 and held it in 1 quarter.
Sculptor Capital's BioNTech position peaked at $163K in Q4 2020.
225 funds tracked by Wall St. Rank held BioNTech as of Q1 2021.

Based on Sculptor Capital's 13F filing for Q1 2021, filed 14 May 2021.